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Abstract
Background: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis 
(FHHNC) is an autosomal recessive tubulopathy characterized by excessive uri-
nary wasting of magnesium and calcium, bilateral nephrocalcinosis, and progressive 
chronic renal failure in childhood or adolescence. FHHNC is caused by mutations 
in CLDN16 and CLDN19, which encode the tight-junction proteins claudin-16 and 
claudin-19, respectively. Most of these mutations are missense mutations and large 
deletions are rare.
Methods: We examined the clinical and biochemical features of a Spanish boy with 
early onset of FHHNC symptoms. Exons and flanking intronic segments of CLDN16 
and CLDN19 were analyzed by direct sequencing. We developed a new assay based 
on Quantitative Multiplex PCR of Short Fluorescent Fragments (QMPSF) to inves-
tigate large CLDN16 deletions.
Results: Genetic analysis revealed two novel compound heterozygous mutations of 
CLDN16, comprising a missense mutation, c.277G>A; p.(Ala93Thr), in one allele, 
and a gross deletion that lacked exons 4 and 5,c.(840+25_?)del, in the other allele. 
The patient inherited these variants from his mother and father, respectively.
Conclusions: Using direct sequencing and our QMPSF assay, we identified the ge-
netic cause of FHHNC in our patient. This QMPSF assay should facilitate the genetic 
diagnosis of FHHNC. Our study provided additional data on the genotypic spectrum 
of the CLDN16 gene.
K E Y W O R D S
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1 |  INTRODUCTION
Loss-of-function mutations in two genes involved in renal 
paracellular reabsorption of calcium and magnesium, 
CLDN16 (OMIM *603959) and CLDN19 (OMIM *610036), 
cause two types of a rare autosomal recessive disease known 
as Familial Hypomagnesemia with Hypercalciuria and 
Nephrocalcinosis, respectively (FHHNC; type 1, OMIM 
#248250 and type 2, #248190) (Konrad et al., 2006; Simon 
et al., 1999). This tubulopathy is characterized by excessive 
urinary losses of renal magnesium and calcium, bilateral 
nephrocalcinosis, and progressive chronic renal failure early 
in life (Claverie-Martin, 2015; Praga et al., 1995). Patients 
usually present with recurrent urinary tract infections, poly-
uria, polydipsia, and nephrolithiasis. The symptoms usually 
appear in early childhood or adolescence. Common bio-
chemical characteristics include low levels of magnesium 
in serum, high urine levels of calcium and magnesium, high 
serum levels of parathyroid hormone, and reduced glomer-
ular filtration rate (Godron et al., 2012; Konrad et al., 2008; 
Weber et al., 2001; Claverie-Martin et al., 2013). Defects in 
enamel formation have been reported in some FHHNC pa-
tients (Bardet et al., 2016; Yamaguti et al., 2017). In addition, 
patients with mutations in CLDN19 display severe ocular ab-
normalities such as myopia, macular colobamata, and nys-
tagmus (Konrad et al., 2006; Claverie-Martin et al., 2013; 
Godron et al., 2012).
CLDN16 and CLDN19 encode tight junction proteins 
claudin-16 and claudin-19, respectively, which are members 
of a family of membrane proteins that contain four transmem-
brane domains, two extracellular loops, a cytoplasmic loop, 
and cytoplasmic amino- and carboxy ends (Meoli & Günzel, 
2020; Suzuki et al., 2014). Both claudins interact with each 
other on adjacent epithelial cells of the thick ascending loop 
of Henle to form a cation paracellular selective barrier that 
regulates the paracellular reabsorption of magnesium and 
calcium in the kidney (Hou et al., 2008). Claudin-16 and 
claudin-19 are also expressed in the tight junction of amelo-
blasts, which might explain their association with defective 
enamel formation in FHHNC patients (Bardet et al., 2016; 
Yamaguti et al., 2017). Moreover, severe ocular involvement 
in FHHNC patients with mutation in claudin-19 might be 
attributed to the expression of this claudin in fetal retinal 
pigment epithelium (Peng, Rao, Adelman, & Rizzolo, 2011; 
Wang et al., 2019).
The clinical diagnosis of FHHNC needs to be confirmed 
by the detection of CLDN16 or CLDN19 pathogenic variants 
in both alleles. Most CLDN16 and CLDN19 variants identi-
fied in FHHNC patients are missense mutations found in ho-
mozygous or compound heterozygous state (Claverie-Martin 
et al., 2015; Prot-Bertoye & Houillier, 2020). These muta-
tions are mainly located in the two extracellular loops but a 
few affect the transmembrane domains and the cytoplasmic 
regions. Only one large deletion has been identified in the 
CLDN16 gene of a patient with FHHNC (Yamaguti et al., 
2015).
In this study, we aimed to describe the clinical and ge-
netic features of a patient with early onset of the first FHHNC 
symptoms. Since direct DNA sequencing of coding exons 
and flanking intronic sequences only detected a missense het-
erozygous mutation of CLDN16, we designed a Quantitative 
Multiplex PCR of Short Fluorescent Fragments (QMPSF) 
assay to identify a novel large deletion in the other allele.
2 |  MATERIALS AND METHODS
2.1 | Ethical compliance
The Ethics Committee of Hospital Universitario Nuestra 
Señora de Candelaria (Santa Cruz de Tenerife, Spain) ap-
proved the protocols of this study, which was conducted 
according to the Declaration of Helsinki. Written informed 
consent was obtained from the patient's parents.
2.2 | Genomic DNA purification and direct 
sequence analysis
After obtaining written informed consent, peripheral blood 
samples of patients and relatives were collected for genetic 
analysis. Genomic DNA was extracted using the GenElute 
Blood Genomic DNA kit (Sigma-Aldrich, St. Louis, MO, 
USA) following the manufacturer's instructions. The cod-
ing exons and flanking intronic sequences of CLDN16 and 
CLDN19 were amplified by polymerase chain reaction (PCR) 
using primers and conditions previously described (Claverie-
Martin et al., 2013; Perdomo-Ramirez et al., 2019; Simon 
et al., 1999). PCR products were purified with the QIAquick 
PCR purification kit (Qiagen, Hilden, Germany) and se-
quenced with the BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems, Foster City, CA, USA). Sequence 
reactions were purified with Performa®DTR Gel Filtration 
Cartridges (EdgeBio BioSystems, Gaithersburg, Maryland, 
USA), and analyzed on a 3500 Series Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA). Mutations 
were identified by comparison to the respective reference 
sequences (GenBank accession numbers NG_008993.1 and 
NG_008149.1, for CLDN19 and CLDN16, respectively), and 
confirmed by sequencing additional independent amplifi-
cation products. We inspected several databases, including 
ClinVar (https://www.ncbi.nlm.nih.gov/clinv ar/), Human 
Gene Mutation database (HGMD, http://www.hgmd.cf.ac.
uk/ac/index.php), 1000 Genomes Project (http://www.1000g 
enomes.org/), and gnomAD database (https://gnomad.broad 
insti tute.org/), to verify that the variant detected in our patient 
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was not a common polymorphism and to confirm that it was 
novel. There are two potential start codons (methionine 1 and 
methionine 71) in the CLDN16 gene that would produce a 
short (235 amino acids) or a long (305 amino acids) clau-
din-16 isoform (Hou, Paul, & Goodenough, 2005; Weber 
et al., 2001). It is currently unknown whether both iso-
forms are functional. For all CLDN16 mutations described 
in the literature, nucleotide numbering starts with the A of 
the first ATG translation initiation site as nucleotide 1 (see, 
table 4 of Prot-Bertoye & Houillier, 2020, and HGMD). 
We used this same numbering for the two mutations de-
scribed here (Reference NCBI sequence used for numbering: 
NM_006580.3). We followed the recommendations of the 
Human Genome Variation Society (http://varno men.hgvs.
org/) for the description of sequence variants.
2.3 | Quantitative Multiplex PCR of Short 
Fluorescent Fragments analysis
In order to detect the potential gross deletions or duplications 
in the CLDN16 region, we used a QMPSF assay. Primer pairs 
for amplification of short exonic fragments corresponding to 
exons 1–5 of the CLDN16 gene and a sequence control of the 
HNF1B gene were designed (Table 1). Simultaneous PCR-
amplification was performed in a 20µL reaction mixture con-
taining dNTPs (10 mM), MgCl2, 10% DMSO, KAPA Taq 
DNA Polymerase (Kapabiosystems, Boston, Massachusetts), 
dye-labeled primers (0.3 µM of each primer), and 40 ng of 
genomic DNA. The amplification conditions consisted of 
an initial step of denaturation at 94°C for 5  min, followed 
by 24 cycles of denaturation at 94°C for 20 s, annealing at 
60°C for 20  s, and extension at 72°C for 20  s. A final ex-
tension was performed at 72°C for 10 min. Then, the sam-
ples were denatured and loaded onto an ABI3130xl Genetic 
Analyzer (Life Technologies). We used the GeneMapper® 
Software v. 4.0 (Applied Biosystems, California) for data 
analysis. Normalization was performed by dividing the peak 
height of each amplification product by the peak height of 
the control-amplified product. Finally, the results obtained 
from the test samples were compared with the results from a 
healthy individual and positive control samples.
2.4 | Bioinformatics analysis
The potential detrimental effect of the amino acid substitu-
tion on the structure and function of claudin-16 was evalu-
ated using the following bioinformatics tools, which are 
based on different principles: PolyPhen-2 (http://genet ics.
bwh.harva rd.edu/pph2/) (Adzhubei et al., 2010), Panther 
v.15.0 (http://www.panth erdb.org/tools/ csnpS coreF orm.
jsp) (Tang & Thomas, 2016), MutPred2 (http://mutpr 
ed.mutdb.org/) (Pejaver, Mooney, & Radivojac, 2017), 
MutationTaster2 (http://www.mutat ionta ster.org/) (Schwarz, 
Cooper, Schuelke, & Seelow, 2014), and Fathmm-XF (http://
fathmm.bioco mpute.org.uk/fathm m-xf/) (Rogers et al., 
2018). The protein sequence of human claudin-16 was ob-
tained from the Uniprot database (https://www.unipr ot.org/, 
entry identifier Q9Y5I7). Protein stability changes resulting 
from the missense variant were estimated using web-based 
programs MUpro (http://mupro.prote omics.ics.uci.edu/) 
(Cheng, Randall, & Baldi, 2006) and I-Mutant 3.0 (http://
gpcr2.bioco mp.unibo.it/cgi/predi ctors/ I-Mutan t3.0/I-Mutan 
t3.0.cgi) (Capriotti, Fariselli, & Casadio, 2005). These tools 
provide the predicted free energy change value (DDG) and 
the sign of the prediction. The DDG value is calculated from 
the unfolding Gibbs free energy value of the mutant protein 
minus the unfolding Gibbs free energy value of the wild type 
(kcal/mol). A DDG value below 0 means that the stability 
of the protein has decreased, whereas a DDG superior to 0 
means it has increased.
2.5 | Protein modeling
There is no experimentally determined 3D structure avail-
able for claudin-16 protein in the Protein Data Bank (PDB). 
T A B L E  1  Primer used for QMPSF analysis of the human CLDN16 gene
Exona Forward primer (5′–3′) Reverse primer (5′–3′)
Amplicon 
size (bp)
1 GACCACCACTAGCCCACAGT 56-FAM-TGGTACCTGGCAATGTGAAA 243
2 AATGCTTTTGATGGGATTCG 56-FAM-CCATTACAAACTGGACCGAAC 185
3 TGGTAACTCGAGCGTTGATG 56-FAM-GTTGCTAGTCCAGCCAGACC 181
4 CCAGGAATCATTGGCTCTGT 56-FAM-GAACAGCTCCAGCCAAAAAG 160
5 TTGGACCTGAGAGAAACTATCCTT 56-FAM-AGCATACATTTTGGCCGTCT 113
Controlb 56-FAM-TGTCTAGTGAGGACCCTTGG GGATCTCTCGTTGCTTTCTG 199
aNumbering is according to DNA sequence (Ensembl: ENST00000264734.2). 
bHNF1B gene. 
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Therefore, wild-type and mutant claudin-16 were modeled 
using the SWISS-MODEL server (Waterhouse et al., 2018) 
(https://swiss model.expasy.org/). Protein sequences in 
FASTA format were uploaded and modeled with the crystal 
structure of human claudin-4 in complex with the C-terminal 
fragment of Clostridium perfringens enterotoxin (PDBe: 
5b2g.2) (Shinoda et al., 2016).
3 |  RESULTS
3.1 | Clinical description
An 11  month old previously healthy boy consulted for 
fever and respiratory symptoms, and leukocyturia was 
identified incidentally. Urinary tract infection was sus-
pected but the finding by renal ultrasound of severe and 
bilateral nephrocalcinosis led to additional diagnostic 
work-up. His physical exam, height, and weight were 
normal by age (percentile >99), as well as his blood pres-
sure. Previously unnoticed polyuria and hyposthenuria 
were also identified. Biochemistry serum tests revealed 
increased creatinine (0.61  mg/dl) [estimated Glomerular 
Filtration Rate (eGFR): 56 ml/min/1.73 m2)], without asso-
ciated electrolytes anomalies (potassium 5.3 mEq/L, chlo-
ride 106 mEq/L, total calcium 10.2 mg/dl, and phosphorus 
4.9  mg/dl) except mild hypomagnesemia (magnesium 
1.54 mg/dl) and elevated uric acid (7.4 mg/dl), and remark-
ably significant high intact parathyroid hormone (175 pg/
ml), for the degree of renal function impairment, with 
adequate 25-hydroxy-vitamin D levels (25  ng/dl). Acid-
base balance was preserved. Urine exam demonstrated in-
creased urinary calcium and magnesium excretion: urinary 
calcium/creatinine (UCa/Cr) 0.39  mg/mg, urinary magne-
sium/creatinine (UMg/Cr) 0.21  mg/mg (at the high-normal 
level but inappropriately increased for the level of serum 
magnesium), and elevated fractional excretion of magne-
sium (FEMg, 8.2%). At the age of 2 years, under the clinical 
suspect of FHHNC, genetic analysis was performed (see, 
below). The patient's follow-up 7 years later was consist-
ent with FHHNC with moderate chronic kidney disease 
(serum creatinine 1.16 mg/dl (eGFR: 40 ml/min/1.73 m2), 
persistent hypomagnesemia despite oral supplements 
(magnesium 1.3  mg/dL) due to maintained hypermagne-
siuria (UMg/Cr 0.27 mg/mg, FEMg 24%), associated with sig-
nificant hypercalciuria (UCa/Cr 0.42 mg/mg; VCa 5.4 mg/
Kg/day). His PTH levels were normalized under medical 
treatment. Dentistry careful evaluation did not demonstrate 
any enamel defects. Furthermore, the patient had no ocu-
lar abnormalities. His parents are not consanguineous, and 
there is no family history of nephropathy except a maternal 
great grandmother with a single kidney and nephrolithiasis.
3.2 | Detection of a novel CLDN16missense 
mutation by direct DNA sequencing
DNA sequence analysis showed that the CLDN19 coding 
exons and their flanking intronic regions had the normal se-
quence. Analysis of the CLDN16 gene revealed a heterozy-
gous variant c.277G>A, in exon 1 (Figure 1a). This variant 
was also detected in heterozygosis in the patient's mother, 
who was unaffected. Sequence analysis of the patient's fa-
ther and brother, both healthy, showed the CLDN16 normal 
sequence (Figure 1a). The pedigree of the family is shown 
in Figure 1b.The G to A substitution leads to the replace-
ment of alanine for threonine in residue 93 of the claudin-16 
protein, p.(Ala93Thr). Alanine 93 is located next to the last 
amino acid of the first transmembrane domain (Figure 1c), 
and is highly conserved throughout the evolution (Figure 
1d). We searched several databases to verify that the vari-
ant detected in our patient, c.277G>A; p.(Ala93Thr), was 
not a common SNP and to confirm that it was a novel muta-
tion not previously reported. This variant was not found in 
ClinVar, HGMDor 1000 Genomes Project database. In the 
gnomAD database, it was found in only one allele from a 
genome sample from African population with a frequency 
of 0.00003 (variant ID: 3-190106185-G-A). In silico predic-
tion tools PolyPhen-2, Panther, MutPred2, MutationTaster, 
and Fathmm-XF indicated that this rare variant was probably 
pathogenic (Table 2). Furthermore, this variant caused a de-
crease in claudin-16 protein stability according to programs 
that predict the protein stability of mutated proteins including 
I-Mutant 3.0 (DDG in kcal/mol: −1.51).We submitted this 
new missense CLDN16 mutation to ClinVar and it was in-
cluded with accession number VCV000930213.1.
3.3 | Identification by QMPSF of a new 
CLDN16 deletion
Direct sequencing of CLDN16 revealed only a mutated allele, 
therefore, since FHHNC is an autosomal recessive disease, 
we suspected that the mutation in the other allele was a large 
heterozygous deletion in this gene. In order to detect a po-
tential heterozygous deletion of CLDN16 that could explain 
the clinical phenotype and to map precisely the deletion, we 
designed a QMPSF assay, a method based on simultaneous 
amplification of multiple short sequences under quantitative 
conditions. The results of this assay revealed a novel large de-
letion in the CLDN16 gene of the patient that, at least, lacked 
exons 4 and 5, c.(840+25_?)del. As illustrated by Figure 2, 
exonic deletions were easily detected by a 50%decrease of 
the corresponding peaks; the probes designed for exons 4 and 
5 presented half the expected signal in the patient, brother 
and father. In contrast, exons 1, 2, and 3 were not deleted. 
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F I G U R E  1  Identification of novel CLDN16 heterozygous missense mutation c.277G>A; p.(Ala93Thr) in patient with FHHNC. (a) 
Electropherograms showing the heterozygous substitution in exon 1 of the patient and his mother. Arrows indicate the position affected by the 
mutation in the patient and his mother. The brother and father revealed the normal sequence. (b) Pedigree of the family showing segregation of 
both CLDN16 variants (missense mutation and deletion in blue and black, respectively). Circle, female individual; squares, male individual; P, 
proband; del, c.(840+25_?)del detected in the other allele. The patient inherited the missense mutation and the deletion from his mother and father, 
respectively. (c) Schematic representation of the CLDN16 gene, cDNA, and claudin-16 protein. Arrows indicate the position affected by missense 
mutation c.277G>A; p.(Ala93Thr). Colored boxes represent the five coding exons and black lines indicate intron sequences; exons missing in 
the deletion mutant are in red. Exons and introns sizes are not at scale. The positions of the ATG start codon and the TAA stop codon are also 
shown. Exons are associated by dotted lines to the schematic representation of the claudin-16 protein where transmembrane domains (TM1–TM4), 
extracellular segments (EC1 and EC2) and cytoplasmic regions (white boxes) are indicated. (d) Multiple sequence alignment of claudin-16 or 
related proteins from different species showing evolutionary conservation of alanine 93. 1T. rubripes does not contain the ortholog for mammalian 
claudin-16. The sequence shown is that of claudin-11B
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The patient's unaffected brother and father were found to be 
carriers of this deletion (Figure 2). This novel CLDN16 dele-
tion was submitted to ClinVar and it was included with ac-
cession number SCV001335520.
3.4 | Modeling of claudin-16 
protein structure
To analyze the structural impact of the two CLDN16 muta-
tions detected in the patient, the 3D structure of the claudin-16 
protein was modeled based on the solved protein structure of 
claudin-4 using SWISS-MODEL. The results did not reveal 
any derangement in the structure of the mutant claudin-16 
protein with the missense mutation (Figure 3). The predicted 
3D structure of the claudin-16 protein encoded by the allele 
with the deletion of exons 4 and 5 resulted in the removal 
of nine amino acids of the third transmembrane domain, the 
second extracellular loop, the fourth transmembrane domain 
(encoded by exon 4) and the carboxy-terminal cytoplasmic 
region containing a PDZ-binding motif and potential phos-
phorylation sites (encoded by exon 5) (Figure 3).
4 |  DISCUSSION
FHHNC is a rare hereditary disease characterized by 
excessive renal losses of magnesium and calcium, 
T A B L E  2  Pathogenicity prediction for claudin-16 mutation p.(Ala93Thr) using bioinformatics tools
Tool PolyPhen-2a Pantherb MutPred2c MutationTasterd 
Fathmm-
XFe 
Score 0.85 362 0.747 58 0.615
Significance Possibly damaging Possibly damaging Probably pathogenic Disease causing Pathogenic
aThe PolyPhen-2 score varies from 0 to 1 Variants with scores in the range 0.85 to 1.0 are more confidently predicted to be damaging. 
bPanther measures the length of time (in millions of years, my) an amino acid position in the protein has been preserved. The longer a position has been preserved, the 
more likely that amino acid change will have a deleterious effect. The thresholds are: probably damaging (preservation time is greater than 450 my), possibly damaging 
(preservation time is between 200 my and 450 my), and probably benign (preservation time is less than 200 my). 
cThe MutPred2 prediction ranges from 0.0 and 1.0, in which a higher score indicates a greater propensity to be pathogenic. 
dThe MutationTaster score ranges from 0.0 to 215. It is derived from the Grantham Matrix for amino acid substitutions and shows the physicochemical difference 
between the original and the mutated amino acid. 
eFathmm-XF predictions are given as p-values in the range 0–1: values above 0.5 are predicted to be deleterious, while those below 0.5 are predicted to be neutral or 
benign. 
F I G U R E  2  Detection of the CLDN16 
deletion using a QMPSF assay. Panels 
show the QMPSF electropherograms of: 
(a) normal control, (b) proband, (c) brother, 
and (d) father. Blue peaks and red peaks 
correspond to CLDN16 exons 1–5 fragments 
and molecular weight markers, respectively. 
The Y-axis indicates fluorescence in 
arbitrary units, and the X-axis displays the 
size in base pairs. The heterozygous deletion 
is easily detected by a reduction of the peaks 
corresponding to exons 4 and 5 (arrows) 
in the proband, his brother and father 
compared to a normal control
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bilateral nephrocalcinosis, and progressive chronic renal fail-
ure (Claverie-Martin, 2015; Praga et al., 1995). Clinical ob-
servations and clearance studies in patients suggested that the 
primary defect was associated with reduced paracellular re-
absorption of magnesium and calcium in the thick ascending 
loop of Henle (Rodriguez-Soriano, Vallo, & Garcia-Fuentes, 
1987). The disease is caused by loss-of-function mutations 
ofCLDN16 (previously known as PCLN1) (type 1), (Simon 
et al., 1999) or CLDN19 (type 2).The majority of Spanish 
patients with FHHNC are homozygous for CLDN19 founder 
mutation p.(Gly20Asp), and they also have severe ocular 
defects (Konrad et al., 2006, Claverie-Martin et al., 2013; 
Martin-Nuñez et al., 2015). We examined the phenotype 
and genotype of a Spanish child with the typical character-
istics of FHHNC and no ocular abnormalities. He suffered 
from polyuria and hyposthenuria. Bilateral nephrocalcinosis, 
mild hypomagnesemia, hypercalciuria, elevated fractional 
excretion of magnesium, increased parathyroid hormone, 
and decreased glomerular filtration rate were found. Genetic 
analysis of the proband and family members revealed two 
novel mutations of CLDN16 in a compound heterozygous 
state, which confirmed the clinical diagnosis of FHHNC type 
1.
The CLDN16 gene is located on chromosome 3q27, and 
to date, 69 pathogenic mutations have been identified: 43 
missense, 10 nonsense, 5 splicing, 5 small deletions, 2 small 
insertion, 2 small indels, 1 complex, and 1 gross deletion 
(Prot-Bertoye & Houillier, 2020). Because of the autosomal 
recessive pattern of inheritance in FHHNC type 1, patients 
are homozygous or compound heterozygous for the particular 
mutations. Functional studies have shown that CLDN16 mu-
tations may cause partial or complete loss of claudin-16 func-
tion (Hou et al., 2005; Kausalya et al., 2006; Konrad et al., 
2008; Müller et al., 2003). The majority of mutant claudin-16 
proteins display normal trafficking to the cell membrane, but 
others remain in the endoplasmic reticulum, Golgi apparatus, 
or lysosomes. Even mutant proteins that are correctly local-
ized to the tight junction frequently show defective magne-
sium paracellular transport (Hou et al., 2005; Konrad et al., 
2008). Hou and colleagues have shown that claudin-16 inter-
acts with claudin-19 conferring cation selectivity to the tight 
junction in a synergistic manner (Hou et al., 2008). Mutations 
that disturb this interaction cause loss of cation selectivity.
Direct sequencing of CLDN16 exons identified heterozy-
gous missense variant c.277G>A; p.(Ala93Thr) in our pa-
tient, which was inherited from his mother. This very rare 
variant, which results in the replacement of an alanine residue 
for threonine, has not been described previously in FHHNC. 
The substitution of a hydrophobic amino acid for a polar 
amino acid in the first transmembrane domain of claudin-16 
could lead to misfolding or defects in membrane insertion. 
Therefore, p.(Ala93Thr) could affect the formation of clau-
din-16/claudin-19 tight junctions. We consider this variant is 
a pathogenic mutation based on the following: (1) it affects a 
highly conserved amino acid residue, (2) bioinformatics anal-
ysis predicts deleterious consequences, (3) it's extremely low 
frequency, and (4) it results in a decrease of protein stability. 
However, this would have to be confirmed experimentally by 
functional analysis. Most CLDN16 mutations affect the two 
extracellular loops of the protein, and only two previously re-
ported missense mutations are located in the first transmem-
brane domain, p.(Cys80Tyr) and p.(Gly88Glu) (Prot-Bertoye 
& Houillier, 2020). Functional analysis of p.(Gly88Glu) has 
revealed that this mutation results in a complete loss of func-
tion (Konrad et al., 2008).
Since only one heterozygous mutation of CLDN16 could 
not explain the FHHNC phenotype of our patient, we used 
a QMPSF assay designed by us to detect the mutation in 
the other allele. The results showed a heterozygous dele-
tion of exons 4 and 5 that was inherited from his father. The 
F I G U R E  3  Predicted 3D structures of wild-type and mutant claudin-16 proteins generated using homology modeling with SWISS-MODEL.
TM1 to 4, transmembrane domains 1 to 4; EC1 and EC2, extracellular loops 1 and 2; CS, cytoplasmic segment. (a) Wild type claudin-16. (b) 
Mutant p.(Ala93Thr). Blue arrows indicate the location of the original alanine 93 residue and missense mutation p.(Ala93Thr). The NH2 and 
COOH termini correspond to threonine 70 and cysteine 255, respectively. (c) Deletion mutant lacking part of TM3, EC2, TM4, and COOH 
terminus. The COOH terminus corresponds now to alanine 197. The models are based on template 5b2 g.2 of claudin-14
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claudin-16 protein encoded by this mutant would lack part 
of the third transmembrane domain, the second extracellular 
loop, the fourth transmembrane domain, and the cytoplasmic 
carboxy terminus, which plays an important role in protein 
stability and trafficking to the tight junction (Itoh et al., 1999; 
Müller et al., 2003). Therefore, we assumed that this deletion 
induces a complete loss of function of the mutant claudin-16 
protein. Only one large homozygous deletion in the CLDN16 
gene of a patient with FHHNC has been reported in the litera-
ture (Yamaguti et al., 2015). This deletion was detected using 
a multiplex ligation-dependent probe amplification assay, 
and included exons 2 to 5. CLDN16 large deletions may be 
underestimated, and we suggest that in cases where only one 
mutated allele is detected, the genetic analysis should include 
a method to detect large deletions.
The pathogenesis of chronic renal disease in patients 
with FHHNC remains unclear. The hypercalciuria and 
nephrocalcinosis present in these patients may contribute to 
progression to end-stage renal disease, however, a suitable 
correlation has not been found (Praga et al., 1995). Moreover, 
not all hereditary tubulopathies characterized by nephrocal-
cinosis lead to end-stage renal disease. Other factors related 
to the progression of chronic kidney disease could be the 
activation of the inflammasome by crystal nephropathy or 
the anomalies caused by the defective claudin-16 function 
early in the development of tubular tight junctions (Godron 
et al., 2012; Claverie-Martin et al., 2015). Konrad and col-
leagues have suggested a genotype-phenotype correlation re-
lated to the progression of renal failure in FHHNC patients 
with CLDN16 mutations (Konrad et al., 2008). They found 
that the progression of renal failure is significantly faster in 
patients with complete loss-of-function mutations in both 
alleles as compared with patients with partial loss-of-func-
tion mutations in one or both alleles. As most patients with 
FHHNC, our patient presented the typical characteristics of 
FHHNC, including moderate chronic kidney disease early in 
infanthood. However, during the last 7 years of follow-up, he 
showed a slow deterioration in renal function (eGFR from 
56–40  ml/min/1.73  m2) in comparison with other patients 
(Weber et al., 2001). This suggests that at least one of the two 
mutations detected in the patient has a partial loss of func-
tion. Since the large deletion obviously has a complete loss of 
function, we speculate that p.(Ala93Thr) has a residual clau-
din-16 function that delays progression of renal failure.
In conclusion, we report the clinical and genetic features 
of a Spanish boy with early onset of FHHNC symptoms but 
slow deterioration in renal function. By applying direct DNA 
sequencing and a QMPSF analysis designed by us, two novel 
compound heterozygous pathogenic variants of CLDN16 
were identified; a missense mutation,c.277G>A; p.(Ala-
93Thr), in one allele and a large deletion, c.(840+25_?)del, in 
the other allele. The missense mutation affects the first trans-
membrane domain of claudin-16 and probably conserves a 
residual function, while the deletion involves exons 4 and 5 
and most likely leads to a complete loss of function. These 
mutations were inherited from his mother and father, respec-
tively. Our study provides further insights into the molecu-
lar basis of FHHNC. Moreover, the QMPSF assay described 
here should facilitate the genetic diagnosis of FHHNC.
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